1. Home
  2. ADM vs BIIB Comparison

ADM vs BIIB Comparison

Compare ADM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Archer-Daniels-Midland Company

ADM

Archer-Daniels-Midland Company

N/A

Current Price

$71.25

Market Cap

30.4B

ML Signal

N/A

Logo Biogen Inc.

BIIB

Biogen Inc.

N/A

Current Price

$184.00

Market Cap

27.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADM
BIIB
Founded
1902
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.4B
27.1B
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
ADM
BIIB
Price
$71.25
$184.00
Analyst Decision
Hold
Buy
Analyst Count
5
27
Target Price
$58.80
$195.00
AVG Volume (30 Days)
3.2M
730.4K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
3.14%
N/A
EPS Growth
N/A
N/A
EPS
2.23
8.79
Revenue
$80,269,000,000.00
$9,890,600,000.00
Revenue This Year
$4.49
N/A
Revenue Next Year
$2.32
N/A
P/E Ratio
$29.48
$20.61
Revenue Growth
N/A
2.22
52 Week Low
$40.98
$110.04
52 Week High
$73.72
$202.41

Technical Indicators

Market Signals
Indicator
ADM
BIIB
Relative Strength Index (RSI) 57.09 47.89
Support Level $57.63 $181.24
Resistance Level $73.72 $184.16
Average True Range (ATR) 2.20 4.34
MACD -0.19 -0.58
Stochastic Oscillator 73.64 27.25

Price Performance

Historical Comparison
ADM
BIIB

About ADM Archer-Daniels-Midland Company

Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: